145 related articles for article (PubMed ID: 19549089)
1. Absorption of testosterone gel 1% (Testim) from three different application sites.
Guay AT; Smith TM; Offutt LA
J Sex Med; 2009 Sep; 6(9):2601-10. PubMed ID: 19549089
[TBL] [Abstract][Full Text] [Related]
2. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
[TBL] [Abstract][Full Text] [Related]
4. Testim 1% testosterone gel for the treatment of male hypogonadism.
Bouloux P
Clin Ther; 2005 Mar; 27(3):286-98. PubMed ID: 15878382
[TBL] [Abstract][Full Text] [Related]
5. Review of Testim gel.
McNicholas T; Ong T
Expert Opin Pharmacother; 2006 Mar; 7(4):477-84. PubMed ID: 16503819
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel.
Marbury T; Hamill E; Bachand R; Sebree T; Smith T
Biopharm Drug Dispos; 2003 Apr; 24(3):115-20. PubMed ID: 12673669
[TBL] [Abstract][Full Text] [Related]
7. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function.
McNicholas TA; Dean JD; Mulder H; Carnegie C; Jones NA
BJU Int; 2003 Jan; 91(1):69-74. PubMed ID: 12614254
[TBL] [Abstract][Full Text] [Related]
8. 12-month observation of testosterone replacement effectiveness in a general population of men.
Miner MM; Bhattacharya RK; Blick G; Kushner H; Khera M
Postgrad Med; 2013 Mar; 125(2):8-18. PubMed ID: 23816767
[TBL] [Abstract][Full Text] [Related]
9. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).
Bhattacharya RK; Khera M; Blick G; Kushner H; Miner MM
Clin Interv Aging; 2012; 7():321-30. PubMed ID: 22956867
[TBL] [Abstract][Full Text] [Related]
10. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.
Wang C; Berman N; Longstreth JA; Chuapoco B; Hull L; Steiner B; Faulkner S; Dudley RE; Swerdloff RS
J Clin Endocrinol Metab; 2000 Mar; 85(3):964-9. PubMed ID: 10720024
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men.
Kaufman JM; Miller MG; Garwin JL; Fitzpatrick S; McWhirter C; Brennan JJ
J Sex Med; 2011 Jul; 8(7):2079-89. PubMed ID: 21492400
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men.
Mazer N; Bell D; Wu J; Fischer J; Cosgrove M; Eilers B;
J Sex Med; 2005 Mar; 2(2):213-26. PubMed ID: 16422889
[TBL] [Abstract][Full Text] [Related]
14. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men.
Swerdloff RS; Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Longstreth J; Berman N
J Clin Endocrinol Metab; 2000 Dec; 85(12):4500-10. PubMed ID: 11134099
[TBL] [Abstract][Full Text] [Related]
15. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
[TBL] [Abstract][Full Text] [Related]
16. Effect of application site, clothing barrier, and application site washing on testosterone transfer with a 1.62% testosterone gel.
Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
Curr Med Res Opin; 2012 Feb; 28(2):281-90. PubMed ID: 22188557
[TBL] [Abstract][Full Text] [Related]
17. Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
Blick G; Khera M; Bhattacharya RK; Kushner H; Miner MM
Postgrad Med; 2013 Mar; 125(2):19-29. PubMed ID: 23816768
[TBL] [Abstract][Full Text] [Related]
18. Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption.
Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
Curr Med Res Opin; 2012 Feb; 28(2):291-301. PubMed ID: 22188558
[TBL] [Abstract][Full Text] [Related]
19. Effects of skin washing on systemic absorption of testosterone in hypogonadal males after administration of 1.62% testosterone gel.
Stahlman J; Britto M; Fitzpatrick S; McWhirter C; Testino SA; Brennan JJ; Zumbrunnen TL
Curr Med Res Opin; 2012 Feb; 28(2):271-9. PubMed ID: 22185431
[TBL] [Abstract][Full Text] [Related]
20. Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease.
Brockenbrough AT; Dittrich MO; Page ST; Smith T; Stivelman JC; Bremner WJ
Am J Kidney Dis; 2006 Feb; 47(2):251-62. PubMed ID: 16431254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
